Cargando…

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation

Background: The role of des-γ-carboxy prothrombin (DCP) in patients undergoing radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) needs to be clarified. Materials and methods: 174 HCC patients that underwent RFA were enrolled. We calculated the HLs of DCP from the available values befo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Chih-Chien, Wang, Jing-Houng, Chen, Chien-Hung, Hung, Chao-Hung, Yen, Yi-Hao, Kee, Kwong-Ming, Hu, Tsung-Hui, Tsai, Ming-Chao, Kuo, Yuan-Hung, Lu, Sheng-Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955975/ https://www.ncbi.nlm.nih.gov/pubmed/36832184 http://dx.doi.org/10.3390/diagnostics13040696

Ejemplares similares

Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case
por: Wang, Ming-Hung, et al.
Publicado: (2021)

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
por: Kuo, Yuan-Hung, et al.
Publicado: (2023)

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
por: Chen, Hsin-Yeh, et al.
Publicado: (2020)

Pre-sarcopenia is the prognostic factor of overall survival in early-stage hepatoma patients undergoing radiofrequency ablation
por: Yeh, Wen-Shuo, et al.
Publicado: (2020)

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan
por: Tsai, Ming-Chao, et al.
Publicado: (2021)

Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis
por: Zhu, Rong, et al.
Publicado: (2014)

A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma
por: De, Ji, et al.
Publicado: (2016)

Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function
por: Chien, Tai-Long, et al.
Publicado: (2016)

Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data
por: Yen, Yi-Hao, et al.
Publicado: (2019)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort
por: Yen, Yi-Hao, et al.
Publicado: (2018)

A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation
por: Hung, Chao-Hung, et al.
Publicado: (2017)

Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis
por: Yang, Ming, et al.
Publicado: (2019)

Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib
por: Kee, Kwong-Ming, et al.
Publicado: (2014)

HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
por: Chang, Kuo-Chin, et al.
Publicado: (2022)

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
por: Lee, Yong Kang, et al.
Publicado: (2013)

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C
por: Huang, Chao-Min, et al.
Publicado: (2017)

Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy
por: Huang, Pao-Yuan, et al.
Publicado: (2019)

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram
por: Sun, Ting, et al.
Publicado: (2021)

Thoracoscopic lobectomy for pulmonary vein occlusion after radiofrequency catheter ablation of atrial fibrillation
por: Lo, Chien-Ming, et al.
Publicado: (2016)

Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin
por: Kurokawa, Tomoharu, et al.
Publicado: (2016)

The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy
por: Kuo, Yuan-Hung, et al.
Publicado: (2014)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Alteration of non-protein respiratory quotient after hepatocellular carcinoma treatment can be related to des-γ-carboxy prothrombin before treatment
por: Saito, Masaya, et al.
Publicado: (2012)

Survival Evidence of Local Control for Colorectal Cancer Liver Metastases by Hepatectomy and/or Radiofrequency Ablation
por: Canseco, Lariza Marie, et al.
Publicado: (2023)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma
por: Yamazaki, Shintaro, et al.
Publicado: (2020)

Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection
por: Tsai, Ming-Chao, et al.
Publicado: (2019)

Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation
por: Chu, Michelle Ong, et al.
Publicado: (2018)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019)

Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment
por: Yeh, Jen-Hao, et al.
Publicado: (2015)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
por: Wang, Jing-Houng, et al.
Publicado: (2022)

A Novel LC‐MS/MS Assay for Quantification of Des‐carboxy Prothrombin and Characterization of Warfarin‐Induced Changes
por: Basit, Abdul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0up04c2c7jqorai03be8eo66lo